miRNA in Septic Acute Kidney Injury
Key facts
- Who runs it
- University Hospital Ostrava
- Where
- Czechia2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 211 people enrolled
- Started
- 2 May 2024
- Ended
- 31 Mar 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- Laboratory examination to determine the presence of sepsis
- Laboratory examination to determine the presence of sepsis and acute kidney injury
- Laboratory examination to determine miRNA and biochemical parameters
- Record updated
- 3 June 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- The study group of patients with sepsis with or without acute kidney injury
- age > 18 years
- newly diagnosed sepsis or septic shock with or without acute kidney injury; Healthy volunteers
- no evidence of infection on clinical or laboratory examination
- age > 18 years
- signed informed consent
Who cannot take part
- patients on chronic dialysis treatment, or after renal transplantation; Healthy volunteers
- chronic kidney disease at stage 4 or 5 according to KDIGO recommendations (KDIGO) for chronic kidney disease 2024
- acute or chronic infection
- renal disease
- age < 18 years
- The study group of patients with sepsis with or without acute kidney injury
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Acute kidney injury is a common and serious complication of sepsis and septic shock, which may be associated with a worse outcome of the patient's condition. The exact pathophysiological mechanism of septic acute kidney injury remains a challenge. One of the possible causes appears to be endothelial dysfunction and mitochondrial damage of renal tubular cells. The aim of this study is to identify specific microRNAs associated with these pathophysiological events in sepsis and septic acute kidney injury. And to establish a new potential diagnostic or therapeutic target for the prevention or treatment of septic acute kidney injury.
The 3 groups in the trial
- Critically ill adult septic patients without acute kidney injury
The patients in this group will be screened clinically and by standard laboratory biochemical methods to determine sepsis diagnosis according to SEPSIS 3 (1). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
Treatment: Laboratory examination to determine the presence of sepsis
- Critically ill adult septic patients with acute kidney injury
The patients will be screened clinically and by standard laboratory biochemical methods to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to KDIGO 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
Treatment: Laboratory examination to determine the presence of sepsis and acute kidney injury
- Healthy volunteers
The blood samples for miRNA and biochemical parameters will be collected once, after randomization.
Treatment: Laboratory examination to determine miRNA and biochemical parameters
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Specific miRNA Associated With Endothelial Dysfunction and Mitochondrial Damage in Patients With Septic Acute Kidney Injury
- Publications
- Record updated
- 3 June 2026